Evangelia Bei

Mrs. Evangelia Bei

First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Attikí, Greece
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2020 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
GBGeorgios Benetos
Georgios Benetos
MKMaria Karmpalioti
Maria Karmpalioti
MDMaria Drakopoulou
Maria Drakopoulou
Konstantinos StathogiannisKonstantinos Stathogiannis
Konstantinos Stathogiannis
MXMaria Xanthopoulou
Maria Xanthopoulou
KTKonstantinos Tsioufis
Konstantinos Tsioufis

4 November 2021
Verified
Journal Article
Open access
SBStylian Brili
Stylian Brili
EBEvangelia Bei
Evangelia Bei
NKNikolas G Kounis
Nikolas G Kounis
CCChristina Chrysohoou
Christina Chrysohoou
CAChristos-Konstantinos Antoniou
Christos-Konstantinos Antoniou
CTConstantinos Tsioufis
Constantinos Tsioufis
Rituximab is a monoclonal antibody against the protein CD20. Various lymphomas as well as non-malignant immune disorders are treated with this antibody. Hypersensitivity reactions associated with the use of rituximab include urticaria, hypotension, chest tightness, vomiting, oxygen desaturation and bronchospasm. A very uncommon case of hypertensive crisis and pulmonary edema following rituximab-induced hypersensitivity reaction in an 80-year-old man receiving rituximab for non-Hodgkin lymphoma is reported. Anaphylaxis manifesting as coronary vasospasm following drug treatment, including rituximab, could be proved a serious condition in patients who need specific treatment. In these patients desensitization protocols seem to be mandatory. (www.actabiomedica.it)

1 January 2018 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
George LazarosGeorge Lazaros
George Lazaros
KKKonstantinos Konstantinou
Konstantinos Konstantinou
OKOyrania Katsarou
Oyrania Katsarou
AKAreti Koumeli
Areti Koumeli
EBEvangelia Bei
Evangelia Bei
DTDimitrios Tousoulis
Dimitrios Tousoulis

30 April 2023 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
EBEvangelia Bei
Evangelia Bei
Alexios S AntonopoulosAlexios S Antonopoulos
Alexios S Antonopoulos
GTGeorgios Tsivgoulis
Georgios Tsivgoulis
CVCharalambos Vlachopoulos
Charalambos Vlachopoulos
This is a case report of a patient with Anderson–Fabry disease (AFD) due to the D313Y variant on the a-galactosidase A (GLA) gene on migalastat treatment and severe chronic kidney disease referred to our unit to assess possible cardiac involvement. A 53-year-old man with chronic kidney disease due to AFD and a medical history of revascularized coronary artery disease, chronic atrial fibrillation, and arterial hypertension was referred to our unit for evaluation of possible cardiac involvement in the context of AFD. Biochemical evaluation reported reduced serum alpha-galactosidase A activity and borderline abnormal serum lyso-Gb3 enzyme activity. The patient had also history of acroparesthesias, dermatological presentation of multiple angiokeratomas, severe kidney impairment with an estimated glomerular filtration rate (eGFR) of 30 mL/min/1.73m² by the age of 16, and microalbuminuria that cumulatively set the diagnosis of AFD. Transthoracic echocardiogram showed left ventricular concentric hypertrophy with left ventricular ejection fraction of 45%. Cardiac magnetic resonance showed findings in keeping with ischaemic heart disease (IHD), i.e. akinesia and subendocardial scarring of the basal anterior and the entirety of the septum and the true apex; in addition, there was severe asymmetrical hypertrophy of the basal anteroseptum (max 18 mm), evidence of low-grade myocardial inflammation, and mid-wall fibrosis of the basal inferior and inferolateral wall, suggesting a cardiomyopathic process–myocardial disease which could not be explained solely by IHD or well-controlled hypertension. This is the first case of possible cardiac involvement in a patient with AFD due to the D313Y variant. This case demonstrates the diagnostic challenges of cardiac involvement in AFD, especially in the presence of a concomitant underlying pathology.

21 February 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EBEvangelia Bei
Evangelia Bei
VVVasileios Voudris
Vasileios Voudris
KKKonstantinos Kalogeras
Konstantinos Kalogeras
EVANGELOS OIKONOMOUEVANGELOS OIKONOMOU
EVANGELOS OIKONOMOU
IIIoannis Iakovou
Ioannis Iakovou
MVManolis Vavuranakis
Manolis Vavuranakis
A few data exist on the differences of implantable aortic valve bio-prostheses. We investigate three generations of self-expandable aortic valves in terms of the outcomes. Patients undergoing transcatheter aortic valve implantation (TAVI) were allocated into three groups according to the valve type: group A (CoreValveTM), group B (EvolutTMR) and group C (EvolutTMPRO). The implantation depth, device success, electrocardiographic parameters, need for permanent pacemaker (PPM), and paravalvular leak (PVL) were assessed. In the study, 129 patients were included. The final implantation depth did not differ among the groups (p = 0.07). CoreValveTM presented greater upward jump of the valve at release (2.88 ± 2.33 mm vs. 1.48 ± 1.09 mm and 1.71 ± 1.35 mm, for groups A, B, and C, respectively, p = 0.011). The device success (at least 98% for all groups, p = 1.00) and PVL rates (67% vs. 58%, vs. 60% for groups A, B, and C, respectively, p = 0.64) did not differ. PPM implantation within 24 h (33% vs. 19% vs. 7% for groups A, B, and C, respectively, p = 0.006) and until discharge (group A: 38% vs. group B: 19% and group C: 9%, p = 0.005) was lower in the newer generation valves. Newer generation valves present better device positioning, more predictable deployment, and fewer rates of PPM implantation. No significant difference in PVL was observed.

1 May 2021 in JACC
Verified
Journal Article
Closed access
CKCharalampos Kalantzis
Charalampos Kalantzis
MVMichael Vavuranakis
Michael Vavuranakis
KKKonstantinos Kalogeras
Konstantinos Kalogeras
EBEvangelia Bei
Evangelia Bei
CMCarmen Maria Moldovan
Carmen Maria Moldovan
MVManolis Vavuranakis
Manolis Vavuranakis